To include your compound in the COVID-19 Resource Center, submit it here.

Anti-NKG2a: Phase I started

Novo Nordisk disclosed in its 1H11 earnings that in May it began a double-blind, placebo-controlled, dose-escalation,

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE